Yousif Capital Management LLC Sells 3,236 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Yousif Capital Management LLC reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 2.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 147,738 shares of the biopharmaceutical company's stock after selling 3,236 shares during the period. Yousif Capital Management LLC's holdings in Gilead Sciences were worth $16,554,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. Octavia Wealth Advisors LLC bought a new position in shares of Gilead Sciences in the first quarter worth $211,000. Investment Advisory Group LLC bought a new stake in Gilead Sciences during the first quarter valued at $218,000. Tounjian Advisory Partners LLC bought a new stake in Gilead Sciences during the first quarter valued at $424,000. Farther Finance Advisors LLC boosted its stake in Gilead Sciences by 94.3% during the first quarter. Farther Finance Advisors LLC now owns 37,487 shares of the biopharmaceutical company's stock valued at $4,172,000 after buying an additional 18,194 shares during the period. Finally, CHICAGO TRUST Co NA bought a new stake in Gilead Sciences during the first quarter valued at $258,000. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Trading Down 0.7%

NASDAQ:GILD traded down $0.79 during mid-day trading on Wednesday, reaching $109.30. 6,413,391 shares of the company's stock traded hands, compared to its average volume of 7,741,190. Gilead Sciences, Inc. has a 12-month low of $62.69 and a 12-month high of $119.96. The firm has a market capitalization of $135.96 billion, a price-to-earnings ratio of 295.41, a PEG ratio of 0.71 and a beta of 0.29. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The company has a 50 day moving average price of $105.36 and a 200-day moving average price of $101.86.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The company had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. During the same quarter in the previous year, the business earned ($1.32) EPS. Gilead Sciences's revenue was down .3% compared to the same quarter last year. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be given a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 2.89%. Gilead Sciences's payout ratio is 66.53%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, May 30th. The stock was sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the sale, the chief executive officer now directly owns 620,268 shares of the company's stock, valued at approximately $68,489,992.56. The trade was a 1.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the sale, the insider now directly owns 121,152 shares in the company, valued at approximately $13,026,263.04. The trade was a 18.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 43,000 shares of company stock valued at $4,630,310. 0.27% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Bank of America lifted their price objective on Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Wells Fargo & Company lifted their price objective on Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. BMO Capital Markets lifted their price objective on Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research note on Wednesday, February 12th. DZ Bank raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective for the company in a research note on Thursday, February 13th. Finally, Morgan Stanley lifted their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. Nine research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, Gilead Sciences presently has an average rating of "Moderate Buy" and an average target price of $110.55.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.